NCT02167854 2021-07-09Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast CancerMemorial Sloan Kettering Cancer CenterPhase 1 Completed23 enrolled